NCT01121302View on ClinicalTrials.gov

Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Tolerability
Interventions
DRUG

AZD5213

0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses

DRUG

Placebo

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY